Company: TELO
Filing Date: 2025-11-20
Form Type: PREM14A
Source: 0001493152-25-024463
Chunk: 116

Company: Telomir Pharmaceuticals, Inc.
Filing Date: 2025-11-20
Form: PREM14A
Chunk 116
---
, 2024 or December 31, 2023.

Tax Fees.

There were no fees billed by Salberg for professional services rendered for tax compliance for the years ended December 31, 2024 or December 31, 2023.

All Other Fees. None

The Audit Committee of our board of directors has established its pre-approval policies and procedures, pursuant to which the Audit Committee approved the foregoing audit and non-audit services provided by Salberg in 2024. Consistent with the Audit Committee’s responsibility for engaging our independent auditors, all audit and permitted non-audit services require pre-approval by the Audit Committee. The full Audit Committee approves proposed services and fee estimates for these services. The Audit Committee chairperson has been designated by the Audit Committee to approve any audit-related services arising during the year that were not pre-approved by the Audit Committee. Any non-audit service must be approved by the full Audit Committee. Services approved by the Audit Committee chairperson are communicated to the full Audit Committee at its next regular meeting and the Audit Committee reviews services and fees for the fiscal year at each such meeting. Pursuant to these procedures, the Audit Committee approved the foregoing services provided by Salberg.

Vote Required

The affirmative vote of a majority of the voting power present or represented by proxy is required to approve the Auditor Appointment Proposal. Abstentions represent the voting power present under the Company’s amended and restated bylaws, and accordingly will have the same effect as a vote “AGAINST” the outcome of this Proposal 3.

<div align='center'>THE BOARD OF DIRECTORS RECOMMENDS THAT THE STOCKHOLDERS VOTE “FOR” THE APPROVAL OF THE AUDITOR.</div>

| 67 |

<div align='center'>PROPOSAL 4. AMENDMENTS TO THE COMPANY’S 2023 OMNIBUS INCENTIVE PLAN TO INCREASE THE NUMBER OF SHARES AVAILABLE FOR ISSUANCE</div>

Overview

At the Annual Meeting, stockholders are also being asked to approve the following amendments to the Plan:

| ● | to                                                                                                                                   
 increase the number of shares reserved under the Plan from 6,500,000 to 8,500,000 (the “Share Plan Increase”);                       
 and                                                                                                                                  |
| ● | to                                                                                                                                   
 allow for the repricing of options or stock appreciation rights (“SARs”), including reducing the exercise or grant price             
 of an outstanding options or SAR, as determined by the Administrator with required approval by the Board,